

Mouwasat Medical Services Co.

Upgrade to Overweight stance on industry-leading margins and the highest dividend yield in our healthcare coverage universe

Rating: Overweight | Target Price: SAR 83.6


July 27, 2026

Market Data		Valuations	2025a	2026e	2027f	2028f	2029f
Last Price (SAR)*	61.0	Net Profit (SAR mn)	822	832	936	988	1,017
Target Price (SAR)	83.6	EPS (SAR)	4.1	4.2	4.7	4.9	5.1
Upside / Downside (%)	37.0	PER (x)	14.8	14.7	13.0	12.3	12.0
Market Cap (bn) (SAR/USD)	12.1/3.2	P/BV (x)	3.1	2.9	2.6	2.4	2.2
52 week High / Low (SAR)	79.7/58.6	DPS (SAR)	2.1	2.5	2.8	3.0	3.1
12-month ADTV (mn) (SAR/USD)	29.5/7.8	Div. Yield (%)	3.5	4.1	4.6	4.8	5.0
YTD Return (%)	-8.5%	RoAE (%)	21.5	20.3	21.0	20.3	19.3
Bloomberg Code	MOUWASAT AB	RoAA (%)	14.4	13.3	13.8	13.7	13.2

*last price as of 26th July 2026

Financials (SAR mn)	2025a	2026e	2027f	2028f	2029f
Revenue	3,223	3,647	4,215	4,455	4,969
COGS	1,861	2,145	2,510	2,658	3,063
Gross profit	1,361	1,501	1,705	1,797	1,906
Gross margin (%)	42.2	41.2	40.4	40.3	38.4
Operating expense	502	562	653	688	765
Operating profit	869	920	1,029	1,085	1,115
Operating margin (%)	27.0	25.2	24.4	24.3	22.4
Net profit	822	832	936	988	1,017
Net margin (%)	25.5	22.8	22.2	22.2	20.5
EPS	4.1	4.2	4.7	4.9	5.1
DPS	2.1	2.5	2.8	3.0	3.1

Price Performance



Source: Tadawul, Bloomberg and anbc research

We reiterate our investment thesis on Mouwasat Medical Services Co. (MOUWASAT), where we expect the company to deliver a net profit of SAR 832.0 mn in 2026e, up 1.2% YoY. Our outlook is backed by (i) industry-leading gross margins; (ii) expansion into the Central Region and other high-density areas; (iii) capacity expansion initiatives that drive growth; and (iv) the highest dividend yield in our universe. We upgrade our rating to "Overweight" from "Neutral" and revise our target price to SAR 83.6/share, implying a potential upside of 37.0% from the last closing price of SAR 61.0/share. Adding a dividend yield of 4.1%, the stock offers a potential total return of 41.1%.

- We expect Mouwasat to report revenue of SAR 3.6 bn in 2026e and to deliver a revenue CAGR of 11.4% between 2025–2029, reaching SAR 5.0 bn by 2029f, driven by ongoing capacity expansion and increasing penetration in Central Province, Jeddah and Madinah regions. Net profit is projected to reach SAR 832.0 mn in 2026e and expected to grow at a CAGR of 5.5% between 2025–2029 to SAR 1.0 bn by 2029f, supported by contributions from new facilities and rising bed capacity.
- Mouwasat's concentration in the Eastern Province, has supported gross margins which average ~45.5% between 2021–2025, the highest in the sector. We expect gross margins to moderate from 42.2% in 2025a to 38.4% in 2029f due to Yanbu and Jeddah hospitals ramp-up, along with openings of three-facilities from mid-2029. Operating margins are also expected to moderate from 27.0% in 2025a to 22.4% in 2029f as higher employee costs and lower ramp-up occupancy will impact the operating profitability. Despite this, we expect Mouwasat to retain the highest gross margin in our healthcare coverage universe throughout the forecasted period, on back of the established Eastern Province base and efficient operating model.
- On the expansion front, the greenfield Yanbu hospital commenced operations in 1H26 and is expected to reach EBITDA breakeven within 15–17 months. The 200 bed Jeddah hospital is scheduled to become operational in 3Q26 and expected to ramp-up fully by 2028. Beyond that, Riyadh, Al-Hofuf and Abha hospitals are expected to commence operations from mid-2029, collectively adding 600 beds and taking total capacity to 2,600 beds by 2029. Total expansion capex is estimated at SAR 2.4 bn through 2029.
- Mouwasat offers a 4.1% dividend yield despite ongoing capex. We upgrade our rating to "Overweight" from "Neutral" stance on the stock with a 2026e P/E of 14.7x and P/B of 2.9x. The stock has declined 22% YoY, underperforming TASI, which fell 2% over the same period.

Ali H. Alshaia

Senior Analyst - Sell-Side Research

Ali.Alshaia@anbcapital.com.sa

+966 11 4062500 Ext. 7065

Disclaimer

anb capital is a Saudi Closed Joint Stock Company with paid up capital of SAR 1,000 million and is licensed by the Capital Market Authority of Saudi Arabia under license number 07072-37 and Unified Number 7001548267, with its head office at 3581 Al Mouyyad Al Jadid, Al Murabba, PO Box 220009, Riyadh 11311, Saudi Arabia, telephone number 800 124 0055.

This report is prepared by anb capital, a full-fledged investment bank providing investment banking, asset management, securities brokerage and research services. anb capital and its affiliates, may have or seek investment banking or other business relationships for which it will receive compensation from the companies that are the subject of this report. Also, anb capital (or its officers, directors or employees) may have a position in the securities that are the subject of this report.

This report has been prepared on the basis of information believed to be reliable, but anb capital makes no guarantee, representation or warranty, express or implied, as to the accuracy, correctness or completeness of such information, nor do they accept any responsibility for loss or damage arising in any way (including by negligence) from errors in, or omissions from the information.

This report is intended only for the recipient to whom the same is delivered by anb capital and should not be reproduced, redistributed, forwarded or relied on by any other person. The distribution of this report in some jurisdictions may be restricted by law, and persons into whose possession this report comes should inform themselves about, and observe, any such restriction.

This report has been prepared by anb capital for information purposes only and is not and does not form part of nor should be considered advice, recommendation, offer for sale or solicitation of any offer to subscribe for, purchase or sell any securities, nor shall it or any part of it form the basis of or be relied on in connection with any contract or commitment whatsoever, and any views or opinions expressed herein are subject to change without notice.

This report and information contained herein, are provided for informational purpose only and does not take into consideration any investment objective, financial situation or particular needs of any recipient and are not designed with the objective of providing information to any particular recipient and only provides general information. anb capital assumes that each recipient would make its own assessment and seek professional advice, including but not limited to, professional legal, financial and accounting advice, before taking any decision in relation to the information provided in the report. Recipients should consider their own investment objectives and financial situation and seek professional advice before making any investment decisions.

Under no circumstance will anb capital nor any of its respective directors, officers or employees be responsible or liable, directly or indirectly, for any damage or loss caused or alleged to be caused by or in connection with the use of or reliance on the information contained in this report.

All opinions, estimates, valuations or projections contained in this report constitute anb capital's current opinions, assumptions or judgment as at the date of this report only and are therefore subject to change without notice. There can be no guarantee that future results or events will be consistent with any such opinions, estimates, valuations or projections. Further, such opinions, forecasts or projections are subject to certain risks, uncertainties and assumptions and future actual outcomes and returns could differ materially from what is forecasted.

Past performance is not necessarily indicative of future performance and the value of an investment may fluctuate. Accordingly, any investment made pursuant to this report in any security is neither capital protected nor guaranteed. The value of the investment and the income from it can fall as well as rise as the investment products are subject to several investment risks, including the possible loss of the principal amount invested. No part of the research analysts' compensation is related to the specific recommendations or views in the research report.

By accepting this report, the recipient agrees to be bound by the foregoing limitations.

Ratings Guidelines

anb capital's investment research is based on the analysis of economic, sector and company fundamentals with the objective of providing a long term (12 month) fair value target for a company.

OVERWEIGHT	NEUTRAL	UNDERWEIGHT
Expected return is more than +15%	Expected return is between +15% & -10%	Expected return is lower than -10%

This report and information contained herein, are provided for informational purpose only and does not take into consideration any investment objective, financial situation or particular needs of any recipient and are not designed with the objective of providing information to any particular recipient and only provides general information. anb capital assumes that each recipient would make its own assessment and seek professional advice, including but not limited to, professional legal, financial and accounting advice, before taking any decision in relation to the information provided in the report. Recipients should consider their own investment objectives and financial situation and seek professional advice before making any investment decisions.

Analyst Certification:

All of the views expressed in this report accurately reflect the personal views of the responsible analyst(s) about any and all of the subject securities or issuers. No part of the compensation of the responsible analyst(s) named herein is, or will be, directly or indirectly, related to the specific recommendations or views expressed by the responsible analyst(s) in this report.

Contact

ANB Capital Head Office

3581 Al Mouyyad Al Jadid, Al Murabba, Riyadh 11311,

PO Box 22009, Kingdom of Saudi Arabia

Tel: +966 11 406 2500, 800 124 0055

Email: research@anbcapital.com.sa

Web: www.anbcapital.com.sa